News & Updates

Following the switch from combination therapy to monotherapy, rheumatoid arthritis (RA) patients with overall lower disease activity (LDA) have higher odds of achieving and remaining in Simplified Disease Activity Index (SDAI) remission/LDA, suggests a study.

In the phase II VELO trial, third-line (3L) treatment with the anti-EGFR* monoclonal antibody (mAb) panitumumab and standard of care (SoC) improved progression-free survival (PFS) in patients with refractory RAS wild-type metastatic colorectal cancer (WT mCRC).

Treatment with retatrutide, the novel agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors, leads to marked reductions in body weight in individuals with obesity, as shown in the results of a phase II trial.

The HEART-FID trial narrowly missed its primary endpoint, showing modest improvement in all-cause mortality, heart failure hospitalizations (hHF), and exercise function with ferric carboxymaltose (FCM) in HFrEF* patients with iron deficiency (ID).

Long-term treatment with golimumab results in relatively low infection rates among patients with rheumatoid arthritis (RA), a study has shown.

Dapagliflozin for individuals with heart failure (HF) demonstrates consistent safety and efficacy across regions worldwide despite geographic differences in patient characteristics, background treatment, and event rates, reports a recent study.